Med-Chemist : "Quintessential Medicinal Chemistry"
Showing posts with label
SCN8A DEEs
.
Show all posts
Showing posts with label
SCN8A DEEs
.
Show all posts
Tuesday, June 30, 2026
Praxis Precision Medicines Announces FDA Acceptance and Priority Review of New Drug Application for Relutrigine in Patients with SCN2A and SCN8A DEEs
›
Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmace...
›
Home
View web version
